Tags

Type your tag names separated by a space and hit enter

[Clinical study of Philadelphia chromosome-positive acute lymphoblastic leukemia].
Zhonghua Xue Ye Xue Za Zhi. 2005 Jan; 26(1):31-4.ZX

Abstract

OBJECTIVE

To study the clinical characteristics and therapeutic outcome of Ph+ acute lymphoblastic leukemia (ALL).

METHODS

Thirty previously untreated cases of Ph+ B-ALL were diagnosed in our institute. The patients were treated with combination chemotherapy of CODP +/- L regimen, Imatinib (400 approximately 600 mg/d) was continuously given to those who couldn't reach CR. Fourteen patients received allogeneic hematopoietic stem cell transplantation (allo-HSCT) after CR, while 16 received consolidation of intensive chemotherapy.

RESULTS

Thirty (32.6%) of 92 ALL patients were diagnosed as Ph+ ALL, with a median age of 25.5 (14 - 60). Among them Ph+ as the sole anomaly was seen in 16 patients, and Ph+ with additional chromosome abnormalities in 14. Besides the B cell markers, 23 (76.7%) patients had CD34+ and 13 (43.3%) CD13+ and/or CD33+. Nineteen of the Ph+ ALL patients underwent molecular analysis; 13 (68.4%) expressed P190 and 6 (31.6%) P210. Increased WBC (> 30 x 10(9)/L) was found in 22/30 cases while WBC > 100 x 10(9)/L in 9/30 cases. The chemotherapy complete remission rate was 68.8% in patients with only Ph+ versus 28.6% in those with additional chromosome abnormalities. All seven refractory/relapsed patients reached CR with Imatinib therapy. The total complete remission rate was 73.3% in all Ph+ ALL patients. The median remission duration was shorter in patients with additional chromosome than in those with only Ph+ (1 vs 7 months, P < 0.05), and so was the survival period (7 vs 9 months, P > 0.05). The remission duration was significantly longer in patients received allo-HSCT than in those received chemotherapy only (8 vs 0.5 month, P < 0.05), and so was the survival period (12.5 vs 6 months, P < 0.05).

CONCLUSION

Additional chromosome abnormalities negatively affect the prognosis and therapeutic effect of Ph+ ALL patients. Imatinib is effective for the induction therapy of Ph+ ALL. The survival period of patients who received allo-HSCT was obviously longer than those who received chemotherapy only.

Authors+Show Affiliations

Institute of Hematology, People's Hospital, Peking University, Beijing 100044, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

chi

PubMed ID

15946506

Citation

Bao, Li, et al. "[Clinical Study of Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia]." Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, vol. 26, no. 1, 2005, pp. 31-4.
Bao L, Jiang B, Huang XJ, et al. [Clinical study of Philadelphia chromosome-positive acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2005;26(1):31-4.
Bao, L., Jiang, B., Huang, X. J., Wang, D. B., Qiu, J. Y., Lu, X. J., Chen, H., & Lu, D. P. (2005). [Clinical study of Philadelphia chromosome-positive acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 26(1), 31-4.
Bao L, et al. [Clinical Study of Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2005;26(1):31-4. PubMed PMID: 15946506.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Clinical study of Philadelphia chromosome-positive acute lymphoblastic leukemia]. AU - Bao,Li, AU - Jiang,Bin, AU - Huang,Xiao-jun, AU - Wang,De-bing, AU - Qiu,Jing-ying, AU - Lu,Xi-jing, AU - Chen,Huan, AU - Lu,Dao-pei, PY - 2005/6/11/pubmed PY - 2009/1/27/medline PY - 2005/6/11/entrez SP - 31 EP - 4 JF - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi JO - Zhonghua Xue Ye Xue Za Zhi VL - 26 IS - 1 N2 - OBJECTIVE: To study the clinical characteristics and therapeutic outcome of Ph+ acute lymphoblastic leukemia (ALL). METHODS: Thirty previously untreated cases of Ph+ B-ALL were diagnosed in our institute. The patients were treated with combination chemotherapy of CODP +/- L regimen, Imatinib (400 approximately 600 mg/d) was continuously given to those who couldn't reach CR. Fourteen patients received allogeneic hematopoietic stem cell transplantation (allo-HSCT) after CR, while 16 received consolidation of intensive chemotherapy. RESULTS: Thirty (32.6%) of 92 ALL patients were diagnosed as Ph+ ALL, with a median age of 25.5 (14 - 60). Among them Ph+ as the sole anomaly was seen in 16 patients, and Ph+ with additional chromosome abnormalities in 14. Besides the B cell markers, 23 (76.7%) patients had CD34+ and 13 (43.3%) CD13+ and/or CD33+. Nineteen of the Ph+ ALL patients underwent molecular analysis; 13 (68.4%) expressed P190 and 6 (31.6%) P210. Increased WBC (> 30 x 10(9)/L) was found in 22/30 cases while WBC > 100 x 10(9)/L in 9/30 cases. The chemotherapy complete remission rate was 68.8% in patients with only Ph+ versus 28.6% in those with additional chromosome abnormalities. All seven refractory/relapsed patients reached CR with Imatinib therapy. The total complete remission rate was 73.3% in all Ph+ ALL patients. The median remission duration was shorter in patients with additional chromosome than in those with only Ph+ (1 vs 7 months, P < 0.05), and so was the survival period (7 vs 9 months, P > 0.05). The remission duration was significantly longer in patients received allo-HSCT than in those received chemotherapy only (8 vs 0.5 month, P < 0.05), and so was the survival period (12.5 vs 6 months, P < 0.05). CONCLUSION: Additional chromosome abnormalities negatively affect the prognosis and therapeutic effect of Ph+ ALL patients. Imatinib is effective for the induction therapy of Ph+ ALL. The survival period of patients who received allo-HSCT was obviously longer than those who received chemotherapy only. SN - 0253-2727 UR - https://www.unboundmedicine.com/medline/citation/15946506/[Clinical_study_of_Philadelphia_chromosome_positive_acute_lymphoblastic_leukemia]_ L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&amp;issn=0253-2727&amp;year=2005&amp;vol=26&amp;issue=1&amp;fpage=31 DB - PRIME DP - Unbound Medicine ER -